Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07166445Recruiting
Using AI to read kidney cancer CT scans for better staging
This study uses a computer program (deep learning) to look at your kidney CT scan and tell if your cancer is more advanced (stage T3) or earlier (stage T1-T2). The goal is to help doctors plan the best treatment for you.
BeijingAges 18–85 - NCT07167329RecruitingPhase 2
Belzutifan for VHL syndrome: a real-world study
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
São Paulo, São PauloAges 14 years+ - NCT07164885Recruiting
RAPART trial for advanced lung cancer patients
This trial tests a treatment for stage 3 lung cancer that cannot be removed with surgery. It includes people who have had other treatments before, like chemo or immunotherapy.
Shenzhen, GuangdongAges 18 years+ - NCT07165769RecruitingPhase 2
ZGR combo for newly diagnosed spleen lymphoma with large cells
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people newly diagnosed with splenic B-cell lymphoma that has large cells (prominent nucleoli). The goal is to see if this drug combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT05384873Recruiting
Immunonutrition to improve immunotherapy in metastatic lung cancer
This trial studies whether adding special nutrition (oral immunonutrition supplements) can help immunotherapy work better in people with metastatic non-small cell lung cancer. Participants receive immunotherapy, with or without chemotherapy, and must be able to take oral supplements.
PaviaAges 18 years+ - NCT05908409RecruitingPhase 1/Phase 2
Testing an investigational drug for blood cancers that came back
This Phase 1/2 trial tests IDP-121 in people with certain blood cancers that have returned or did not respond to available treatments. The goal is to find a safe dose and see whether the treatment can help control the cancer.
Santander, CantabriaAges 18 years+ - NCT06920433RecruitingEarly Phase 1
Targeted cell therapy for tough lupus with kidney involvement
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06738576RecruitingPhase 1
Stem cell treatment for women over 50 with stress urinary incontinence
This trial tests whether a single injection of stem cells from donated fat tissue can help women over 50 with stress urinary incontinence. It is for those who haven't gotten better with exercises or who want to avoid surgery.
Coslada, MadridAges 50 years+ - NCT07162038RecruitingPhase 1
CAR-T cells plus half-matched stem cell transplant for high-risk blood cancer
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
Bethesda, MarylandAges 18–75 - NCT07161882Recruiting
Algerian lung cancer registry study
This study tracks people diagnosed with lung cancer to learn more about the disease and its treatment in Algeria. By joining, you help build a better understanding of lung cancer care.
Algiers, Algiers ProvinceAges 18 years+ - NCT07157670Recruiting
Heart health study after stem cell transplant
This study looks at heart problems that can happen after a stem cell transplant from a donor (allogeneic). It aims to understand these risks better so doctors can help patients stay healthier after transplant.
ParisAges 15 years+ - NCT07162012RecruitingEarly Phase 1
Cell therapy for EBV-positive lymphoma
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
ShanghaiAges 18–70 - NCT07160023Recruiting
Registry study for primary cutaneous T-cell lymphoma
This study follows people with primary cutaneous T-cell lymphoma who are seen at the Dermatology Unit in Pavia. It collects information to better understand the disease and improve care.
Pavia, PaviaAges 6 years+ - NCT07163403RecruitingPhase 1
Preventing cancer in Lynch syndrome carriers with dendritic cell vaccine
This trial tests whether a personalized vaccine made from your own immune cells can help prevent cancer in people with Lynch syndrome. You must have no history of cancer and be willing to have regular colonoscopies.
Barcelona, BarcelonaAges 18 years+ - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
Springdale, ArkansasAges 18 years+ - NCT03964480Recruiting
Registry for newly diagnosed peripheral T-cell lymphoma patients
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
Stanford, CaliforniaAges 18 years+ - NCT07150663RecruitingPhase 3
Megestrol acetate with chemoradiation for stage III lung cancer
This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.
Wuhan, HubeiAges 18–85 - NCT07146672RecruitingPhase 1/Phase 2
Super DC cell injection to prevent cancer recurrence after surgery
This trial tests a new immune cell treatment called Super DC cells to see if it can stop tumors from coming back after they have been surgically removed. It is for people with solid tumors who have had complete removal of the cancer and show no signs of remaining disease on scans.
ShanghaiAges 18–80 - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07151040RecruitingPhase 1/Phase 2
Testing TH9619 for advanced solid tumors
This trial tests a new drug called TH9619 for people with advanced cancers of the colon, head and neck, lung, or stomach. It aims to see if the drug is safe and works against tumors that have already been treated with chemotherapy.
VillejuifAges 18 years+ - NCT07152678RecruitingPhase 2
Brachytherapy with radiation and immunotherapy for esophageal cancer
This trial tests combining brachytherapy (a type of internal radiation) with immunotherapy (nivolumab) for people with advanced esophageal cancer that has not fully responded to initial chemoradiation. The goal is to see if this targeted approach can improve outcomes.
Huwei, Yunlin CountyAges 18–85 - NCT07149649RecruitingPhase 2/Phase 3
Magnesium for advanced lung cancer
This trial tests if adding magnesium supplements to standard first-line treatment (chemotherapy plus immunotherapy) improves outcomes for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It is for patients who have not had prior treatment for metastatic disease.
AarauAges 18 years+ - NCT07153445RecruitingPhase 2
Atezolizumab before and after surgery for stage III lung cancer
This trial tests whether the immunotherapy drug atezolizumab, given before and after surgery, can help treat stage III non-small cell lung cancer that has not spread to other parts of the body. It is for people who have not had any previous cancer treatment for this disease.
Alicante, AlicanteAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.